SALSS 2011 Profiles



SPEAKERS
Thursday August 25th
In order of appearance

Dr. Carl Johan Sundberg,
Head of Bioentrepreneurship,
Karolinska Institutet

Carl Johan Sundberg is Senior University Lecturer in Bioentrepreneurship and heads the Unit for Bioentrepreneurship at Karolinska Institutet. He is a licensed physician and associate professor at the Dept. of Physiology and Pharmacology and also an investment manager at Karolinska Investment Fund. He is the recipient of several prizes, including the European Commission's Descartes Communication Prize for Excellence in Science Communication 2005. He is vice-president of Euroscience and was the initiator of Euroscience Open Forum (www.esof2008.org), a large international science conference on science, technology, business and science communication. Dr. Sundberg is Vice President of Euroscience and has served as member or chairman of numerous company boards, currently e.g. NsGene A/S, Cellectricon AB and Alfta Rehab AB.

Göran Hägglund,
Minister for Health & Social Affairs,
Swedish Government

"In many respects, Swedish health and medical services are world class. However, many people still have to wait too long for treatment, care services are not as equal as they should be and quality problems do exist. These are areas that need to be addressed."
Minister for Health and Social Affairs, 2006–

Richard Bergström,
Director General,
European Federation for Pharmaceutical Industries & Associations

Richard Bergström has been the Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) since April 2011. Previously he served for nine years as the Director-General of LIF, the Swedish Association of the Pharmaceutical Industry, following positions in Switzerland in regulatory affairs at the pharmaceutical companies Roche and Novartis. Mr. Bergström has also been appointed by the Swedish Government to the Board of the Karolinska Institute. He is a pharmacist by training, and received his MScPharm degree from the University of Uppsala, Sweden, in 1988.

Jürg Zürcher,
Partner & EMEIA Biotechnology Leader,
Ernst & Young

Jürg's 24-year career with Ernst & Young has involved extensive audit and corporate finance experience with local and international health sciences clients including Actelion, HBM BioVentures, Roche, Santhera Pharmaceuticals, Schwarz Pharma, Syngenta and Synthes. His experience of having worked with Ernst & Young in the United States has helped him to also successfully transition clients to International Reporting Standards (IFRS or U.S. GAAP). In addition to serving as an audit partner to several venture capital companies, Jürg Zürcher is also active in the VC community, advising clients on fundraising opportunities and facilitating mergers. Jürg Zürcher studied at the University of St. Gallen, where he obtained a degree in Business Administration, with focus on auditing. He is a Swiss Certified Accountant.

Dr. Stefan Larsson,
Senior Partner & Managing Director,
The Boston Consulting Group

Stefan is a Senior Partner of the Boston Consulting Group (BCG), the leader of its Nordic Health care Practice group and the Global leader of BCG's Scientist network. The Boston Consulting Group is a global Management Consulting firm and a leader in the field of Health care Strategy. Stefan joined BCG 1996 and has advised clients across the Health care industry covering strategy, organization and operational improvement projects. In BioPharma he has lead projects throughout the value chain from Preclinical and Clinical Development to Sales Force Effectiveness. He has lead over 40 Due diligence projects for European Private Equity clients. Stefan is the proud father of two teen-agers and spends his past time with wife and friends enjoying art, good food/wine and music. Stefan is an MD from the Karolinska Institute. He did his PhD at the Karolinska Institute and Harvard Medical School and PostDoc at the MRC Human Genetics unit in Edinburgh and at the EMBL in Heidelberg.

Håkan Åström,
Chairman,
Orexo

Håkan Åström is the Chairman of Orexo AB, Ferrosan Holding AS, Affibody Holding AB and PledPharma AB and previously Swedish Orphan Biovitrum AB and Topotarget AS. He is also a board member of Rhenman & Partner Asset Management. Previously Mr. Åström was the CEO of Travenol AB (Baxter Inc.), Astra Pharmaceuticals Ltd and Kabi Pharmacia AB. He was the Head of Strategy and Communication of Pharmacia Corporation and the CEO of Pharmacia AB 1997 – 2003. He was also a board member of Karolinska Institutet 2004-2010. He holds Honorary Doctorate in Medicine at the Sahlgrenska Academy in Gothenburg University in 2003, and Master of Science degree in Business Administration and Economics from the Stockholm School of Economics in 1972.

Dr. Florence P. Haseltine,
Founder,
Society for Women's Health Research

Dr. Haseltine has earned both a Ph.D. and M.D. and is a board certified obstetrician and gynecologist and an expert in reproductive endocrinology. Currently she is working on the basis of gender differences and what these differences teach us about the system and the disease process. She is recognized for her work regarding the health of women and their advancement professionally. She founded and was the first president of the Society for Women's Health Research. This organization has brought the issue of research on women's health to the attention of high federal officials and proficient members of the media as well as placing it on the nation's priority research agenda. Dr Haseltine was on the Board of Directors of the American Association for the Advancement of Science and the Society for Gynecologic Investigation. She has had numerous peer recognitions to include: election to the Institute of Medicine, Weizmann Honored Scientist, a Kass lecturer, a recipient of the American Woman's Medical Association Scientist Award and many others.

Professor Kee Seng Chia,
National University of Singapore

Prof Kee Seng Chia is a medical epidemiologist and has published over 150 papers in journals, authored chapters and edited books in chronic disease epidemiology, molecular epidemiology and occupational health. His current research focus is in molecular epidemiology of chronic diseases and in the direction of the multidisciplinary NUS-GIS Centre for Molecular Epidemiology. To that end, Prof Chia is setting up cohort studies for translational research to elucidate gene-environment interactions in chronic disease causation, prevention and therapy. He is driving the "Singapore Consortium of Cohort Studies" which plans to recruit 250,000 Singaporeans over the next 10 to 20 years.

Patrick Flochel,
Partner & EMEIA Life Science Leader,
Ernst & Young

Patrick Flochel is responsible for coordinating EY relationships with global pharmaceutical, biotechnology and medical devices corporations in the areas of risk, tax, business advisory and transaction services and serves as Global Client Service Partner or as Senior Advisory Partner on several Pharmaceutical clients. Mr. Flochel has served on various management and leadership positions at EY at global and EMEIA levels. Prior to his current position, Mr. Flochel has had a 30 year career in auditing and consulting, starting in 1979 in the Paris office, moving to Brussels in 1989 to lead the EU Policy and Regulation team providing strategic advisory services to Fortune 500 companies. He joined the Change Management practice in Paris in 1995 while setting up the French practice's marketing and communications department and later moved to London as Global Vice-Chair for business development. Mr. Flochel has a Master's degree from ESCP in Paris.

Abe Kasbo,
CEO,
Verasoni

In 2005, Mr. Kasbo founded Verasoni. His vision was to create a firm that, first and foremost, behaved in the best interest of the client while delivering market-leading marketing, public relations, advertising, and web strategies. Since the firm's founding, Verasoni has helped clients in healthcare, financial services, hospitality, government, and professional and business services. Mr. Kasbo has led marketing communications projects for market leaders such as AECOM, Cutera, Bank of America, Lucent Technologies, Pricecare.com, Parkway Dental, and Hurley Medical Center. Mr. Kasbo shares his experiences and knowledge through various publications, his articles have appeared in NJEntrepreneur.com, InBiz Magazine, NJBiz, Healthcare Strategies, and The Journal of Healthcare Management. A frequent speaker at professional conferences, he has served as an adjunct professor at Seton Hall University's Center for Public Service where he taught marketing and public relations. Mr. Kasbo earned a Master's of Public Administration and Bachelor of Arts in Political Science from Seton Hall University.

Dr. Yuval Binur,
General Managing Partner,
Accelerated Technologies Partners

Dr. Binur has over 25 years of venture capital experience in the US, Europe and in Israel. In addition to co-founding ATI, Dr. Binur has been a founding partner of Medica Venture Partners, a global health care and life sciences venture capital fund operating from Israel. For 9 years prior to Medica, Dr Binur was a member of Adler & Co., a major U.S. venture capital firm based in New York. He has been a board member of over 30 venture-backed companies in the areas of pharmaceuticals, medical devices, software and electronics among other boards. Dr. Binur was a director of Percutaneous Valve Technologies, Inc. (PVT), a company that has revolutionized the replacement of heart valves and was sold during 2004 to Edwards Lifesciences, Inc. Dr. Binur holds a B.Sc. degree in electrical engineering and Ph. D. degree in physics.

Ursula Tengelin,
Secretary General,
Cancerfonden

Ursula Tengelin is Secretary General of Cancerfonden (The Swedish Cancer Society) which is an independent non-profit organization. The organizations main task is to raise and distribute money for cancer research. As the principal financier of cancer research in Sweden, Cancerfonden essentially acts as a national research council. Ms. Tengelin is a board member of LKAB, Samhall and Norrland Center AB. Prior to joining Cancerfonden she was CEO of Proffice Sverige AB and President of Hoechst Marion Roussel (now Aventis) in the Nordic countries.

Professor Mathias Uhlén,
The Royal Institute of Technology

Mathias Uhlén is Professor of Microbiology at the Royal Institute of Technology (KTH), Stockholm, Sweden. Dr Uhlen has more than 300 publications in bioscience with the focus on the development and use of affinity reagents in biotechnology and biomedicine. Dr Uhlen is currently working on the Human Protein Resource Project (HPR), with the aim to systematically map the human proteome. At present, the Human Protein Atlas portal (www.proteinatlas.org) contains more than 7 million high-resolution images representing 6,800 human proteins. He has founded several companies, including Pyrosequencing AB (now Biotage AB), Affibody AB, SweTree Technologies AB, Magnetic Biosolutions AB (now Nordiag AS), Atlas Antibodies AB and Creative Peptides AB. He has received numerous awards, including the gold medal of the Royal Swedish Academy of Engineering Sciences, the Most Noble Order of the Seraphim - the Order of His Majesty the King, the HUPO Distinguished Award, KTH Great Prize and the Scheele prize.

Dr. Andrew Hessel,
Founder,
Pink Army Cooperative

Andrew Hessel is an outspoken champion of DNA technologies, catalyzing new project developments, investment, and relationships in synthetic biology and bioengineering. His overarching message is that biology is poised to become the IT industry of the 21st century, fueled by a new generation of young researchers and entrepreneurs armed with technologies like DNA sequencing and DNA synthesis that are becoming exponentially more powerful yet much less expensive. The possible applications are virtually limitless and include the typical global challenges (sustainable fuel production, environmental remediation, and better diagnosis treatment of human disease) but also extend into new, uncharted scientific territories. He co-chairs the Bioinformatics and Biotechnology track at the Singularity University, an institution founded by futurist Ray Kurzweil and X Prize Foundation CEO Peter Diamandis, with sponsorship from world-leading organizations that include Google, Autodesk, and NASA. He is also the founder of the Pink Army Cooperative, an experimental biotechnology venture working to open source personalized cancer therapies. His work has been featured in The New York Times, Futurist Magazine, H+, and Wired News.

Dr. William A. Haseltine,
Chairman,
Haseltine Global Health

Dr. William A. Haseltine, PhD, is Chairman of Haseltine Global Health, LLC, a virtual pharmaceutical company dedicated to developing new and more efficient means to develop new life saving drugs and medical devices. He is also President of the Haseltine Foundation for Medical Sciences and the Arts, a foundation that supports access to high quality health for the poor and middle class of developing countries and that also fosters a dialog between sciences and the arts. He is an Adjunct Professor at The Scripps Institute for Medical Research. Dr. Haseltine has an active career in both Science and Business. He was a professor at Harvard Medical School from 1976-1993 where he was the chair of two academic research departments. He is well known for his pioneering work on cancer and HIV/AIDS. He is the Founder of Human Genome Sciences, Inc and served as the Chairman and CEO of the Company until 2004. He is also the founder of seven other successful biotechnology companies. He serves as an advisor to CMEA, a venture capital company, and to several biotechnology and pharmaceutical companies. Dr. Haseltine is active in public service. He is Co-Chair of the President's Council of the Cold Spring Harbor Laboratory, a member of the Advisory Board of the Global Coalition on HIV/AIDS, a member of the Board of One World Health, a member of the CEO Council of the New York Academy of Science, and Chair of the Berkeley Center of Synthetic Biology. He is a member of the Executive Committee of the Brookings Institution, a member of both the Council on Foreign Relations and the Trilateral Commission, and a member of the Chairman's Circle of the Asia Society.

Professor Thomas Helleday,
University of Oxford & Stockholm University

Thomas Helleday is MRC Professor of Cancer Therapeutics at the Gray Institute for Radiation Oncology and Biology at the University of Oxford and Professor of Molecular Genetics at the Department of Genetics, Microbiology and Toxicology at Stockholm University. He has won numerous prestigious prizes, and his team at The Helleday laboratories is working to find novel anti-cancer therapies. Thomas earned his PhD in molecular biology and a degree in Business Administration and Economics at Stockholm University.

Dr. Elisabet de los Pinos,
CEO,
Aura Biosciences

Elisabet de los Pinos is the founder of Aura Biosciences, which she created from the ground up: from concept, through patents in her name, fundraising and incorporation, to today's pre-clinical research and strategic partnerships. She is passionate about eradicating cancer and is a member of the American Society of Clinical Oncology. Prior to founding Aura, she was Marketing Manager at Eli Lilly & Co where she led the launch of Alimta, a new drug for Non Small Cell Lung Cancer. Before that, she was a post-doctoral Fellow at the Institute for Cancer Research in London. Dr. de los Pinos was recently named as one of Boston Business Journal's Top 40 talents in Boston under the age of 40, a Mass High Tech "Woman to Watch" and one of the ten entrepreneurs that will change your life by Time Magazine. Under her leadership, Aura Biosciences was recognized as a Technology Pioneer by the World Economic Forum. Dr. de los Pinos earned her BA and PhD in Molecular Biology summa cum laude from the University of Barcelona and her MBA from IE Business School. She speaks four different languages and earned an intermediate degree of Music from Liceu of Barcelona School of Music. She serves on the Board of Overseers of Beth Israel Deaconess Medical Center.

Tomas Puusepp,
CEO,
Elekta

Tomas Puusepp is President and CEO of Elekta since 2005. He has a total of 28 years of experience in international medical technology. Following studies in engineering and physics and management training at IMD in Lausanne, Switzerland, Tomas Puusepp held various positions at the Research Institute for Atomic Physics, Scanditronix and Ericsson before being employed by Elekta in 1988. Since then, he has held various management positions within the Company, including head of Elekta’s neurosurgery operations, President of Elekta’s subsidiary in North America and global head of Elekta’s sales, marketing and service operations.

SPEAKERS
Friday August 26th
In order of appearance

Dr. Karin Hehenberger,
Senior Vice President,
Juvenile Diabetes Research Foundation

Karin Hehenberger, M.D., Ph.D., is the Senior Vice President, Strategic Alliances, for the Juvenile Diabetes Research Foundation, where she manages JDRF's scientific, financial and commercial partners. Most recently, Dr. Hehenberger served as Vice President, Metabolics Strategy and Business Development for Johnson & Johnson. In this capacity, Dr. Hehenberger developed the strategic framework for Johnson & Johnson's global metabolic disease efforts. Previously, Dr. Hehenberger was a consultant at McKinsey & Co., where she focused on projects related to diabetes. She has experience in the financial sector, both as a buy-side analyst covering healthcare equities, and as a partner at a global venture capital firm focusing on healthcare. Dr. Hehenberger worked for Eyetech Pharmaceuticals prior to and during its IPO, and on the approval and launch of its product for age-related macular degeneration and diabetic retinopathy. Dr. Hehenberger holds M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden. She continued her research as a post-doctoral fellow at the Joslin Diabetes Center at Harvard Medical School. Dr. Hehenberger is on the Board of The Rolf Luft Foundation for Diabetes Research and The Core Sight Council associated with the Lighthouse foundation.

Fred Hassan,
Chairman,
Bausch + Lomb

Mr. Hassan is a Partner and Managing Director with the private equity firm, Warburg Pincus. He is also Chairman of Bausch & Lomb, as well as Board member of Time Warner and Avon where he serves as Lead Director. He is the former Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation. Prior to joining Schering-Plough in April 2003, Mr. Hassan was Chairman and Chief Executive Officer of Pharmacia Corporation – a company that was formed in March 2000 as a result of the merger of Monsanto and Pharmacia and Upjohn. Mr. Hassan joined Pharmacia & Upjohn as Chief Executive Officer in 1997. Previously, Hassan was Executive Vice President of Wyeth, formerly known as American Home Products, with responsibility for its pharmaceutical and medical products business. He was elected to Wyeth's Board of Directors in 1995. Earlier in his career, he spent 17 years with Sandoz Pharmaceuticals (now Novartis) and headed its U.S. pharmaceuticals business. Mr. Hassan received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School. Hassan has chaired three significant pharmaceutical industry organizations - The Pharmaceutical Research and Manufacturers of America (PhRMA), The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) and the HealthCare Institute of New Jersey (HINJ). Mr. Hassan is a member of The Business Council and the American Institute for Stuttering.

Dr. Eugen Steiner,
Partner,
HealthCap

Eugen Steiner, MD, PhD, is a partner of HealthCap, a leading European health care venture capital fund. Dr. Steiner is a serial entrepreneur and has served as Chief Executive Officer or Chairman of the Board of several biotechnology and biomedical companies, including Affibody, Biolipox, Biostratum, Calab Medical, Creative Peptides, Eurona Medical, Global Genomics, LTB4, PyroSequencing, Melacure Therapeutics and Visual Bioinformatics. Until 1987 Dr. Steiner practiced medicine at the Karolinska University Hospital in Huddinge/Stockholm. He became a specialist in Clinical Pharmacology and was active in pharmacogenetic research at the Karolinska Institute, where he had also received his medical and scientific degrees.

Dr. Samir Tari,
CEO,
PCAsso Diagnostics

Dr. Tari is the main inventor of the PolyChromatic Angiography. After his medical training at Cairo University, Egypt, Dr. Tari joined Columbia University as a post doctoral fellow to perform research on the modulation of the Receptor for Advanced Glycation Endproducts (RAGE). RAGE modulating molecules (s-RAGE) were further developed by TransTech Pharma and were then acquired by Pfizer. After his success in basic science research, Dr. Tari was awarded the Daniel Kirby fellowship in translational research at the Louis V. Gerstner Jr. Clinical Research Center in Vision. During this fellowship, Dr. Tari conceptualized and performed the initial experiments on PolyChromatic Angiography. After Columbia University, Dr. Tari joined the New York Eye and Ear Infirmary to train in uveitis (inflammation of the eye). During his training in uveitis, Dr. Tari was an investigator in 8 industry clinical trials and numerous other academic clinical research projects. After finishing his training in uveitis, Dr. Tari joined Lux Biosciences, an ophthalmic specialty pharmaceutical company, in the capacity of medical director responsible for running 5 phase 3 clinical trials in the US, Canada and India.

Professor Jan Holgersson,
CSO,
Recopharma

Jan holds a professorship in transplantation immunology at the Sahlgrenska Academy, University of Gothenburg (UoG), and has clinical responsibilities as a senior transplant immunologist at the tissue typing laboratory of the Sahlgrenska University Hospital in Gothenburg. He received his M.D. from University of Gothenburg and his Ph.D. in carbohydrate biochemistry from the same institution. After a 3-year post-doc at Department of Molecular Biology/Genetics, Harvard Medical School, he spent 15 years at the Karolinska Institute/Karolinska University Hospital where he established his research group and passed his fellowship in clinical immunology. He is co-founder of Recopharma AB, AbSorber AB and NovaHep AB. Besides being a member of their BoD, he is CSO of Recopharma and NovaHep and Medical Director of AbSorber AB.

Dr. Christina Åkerman,
Director General,
Medical Products Agency

Christina Åkerman is Director General for the Swedish Medical Products Agency. Dr. Åkerman is a trained MD with a specialty in Clinical Pharmacology. She also holds an Executive MBA degree. Previously she served as Medical Director of AstraZeneca Sweden, President of AstraZeneca's subsidiary in the Philippines and VP and Director of Technology and Product Development at Orexo.

Professor Hans Rosling,
Karolinska Institutet

Hans Rosling is Professor of International Health, Karolinska Institutet, Stockholm, Sweden. He discovered konzo, a new epidemic paralytic disease, when serving as doctor in Mozambique 1979-81. Two decades of research in rural Africa traced the cause to toxic, ill-processed cassava roots, hunger and poverty. Professor Rosling co-founded Médecines sans Frontier Sweden, and started courses and wrote a textbook on Global Health. He initiated university collaborations with Asia and Africa and co-founded Gapminder that unveils the beauty of statistics by turning boring numbers into enjoyable animations that make sense of the world.

PRESENTING COMPANIES
Thursday August 25th at 10:00 a.m.

Algeta ASA
NORWAY

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. These alpha-pharmaceuticals harness the unique characteristics of alpha-particle emitters and offer the potential to deliver potent and localized destruction of cancer cells with minimal effect on surrounding normal cells and a favorable side-effect profile. Algeta's initial focus is on treating bone metastases, a serious clinical development of advanced cancer for which few specific treatments exist, and which represents an area of significant commercial potential. The Company's lead product, Alpharadin® (radium-223 chloride), is a first-in-class alpha-pharmaceutical that is being developed under a development and commercialization agreement with Bayer HealthCare Pharmaceuticals AG. In June 2011, a global phase III clinical trial (ALSYMPCA) of Alpharadin to treat bone metastases in patients with castration-resistant prostate cancer (CRPC) was stopped early after meeting its primary endpoint of significantly improving overall survival. Alpharadin is also in clinical trials as a potential new treatment for bone metastases in endocrine-refractory breast cancer patients, and in combination with docetaxel chemotherapy for bone metastases in CRPC patients. Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs), which are based on conjugating the alpha-emitter thorium-227 to tumor-targeting molecules, as a basis of future targeted alpha-pharmaceutical candidates. The Company was founded in 1997 and listed on the Oslo Stock Exchange in 2007 (Ticker: ALGETA).

For further information visit www.algeta.com
or contact Andrew Kay, CEO at andrew.kay@algeta.com

Viropro, Inc.
U.S.A.

Viropro Inc. currently conducts operations through its subsidiaries, Viropro International Inc., Biologics Process Development, Inc. and Alpha Biologics Sdn. Bhd. The company's principal objective is to provide clone-to-manufacturing services to bio/pharmaceutical companies globally. Viropro enjoys close working relations with some of the leading biotech research institutes in North America, one of which, for example, is the Biotech Research Institute (BRI) in Montreal, Canada, a constituent of the National Research Council of Canada. Viropro has exclusively licensed from BRI a high-efficiency expression system platform for antibody production. In April 2010, Viropro acquired 100% of Biologics Process Development (BPD), Inc. (Poway/San Diego, CA) from Intas Biopharmaceuticals Ltd. (IBPL) as part of its strategy to create a global provider of Contract Research and Manufacturing Services specifically for the biotechnology industry. BPD has been providing contract laboratory services to the biotechnology and biopharmaceutical industries for fourteen years. The range of services includes molecular biology, cell culture, fermentation, protein purification, frozen storage, process scale-up and consulting services. BPD has an impressive list of clients that range from university laboratories to well-known biotechnology and biopharmaceutical companies. IBPL is one of India's leading biotechnology companies. It is the only biotech company in India that has an EMEA-approved cGMP biologics facility and has successfully introduced four biopharmaceuticals in the market. In February 2011, Viropro acquired Alpha Biologics Sdn. Bhd. of Penang, Malaysia, in an all-stock transaction.

For further information visit www.viropro.com
or contact Rajiv Datar, CEO at rvdatar@gmail.com

XDx, Inc.
U.S.A.

XDx, Inc., based in the San Francisco Bay Area, is a molecular diagnostics company focused on the discovery, development and commercialization of high clinical impact, non-invasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed AlloMap Molecular Expression Testing, an FDA-cleared test, which provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management. Some of the AlloMap technology developed and implemented by XDx in heart transplant patient management is applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx's non-invasive technology offers the potential to decrease healthcare costs and improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

For further information visit www.xdx.com
or contact Matthew Meyer, Vice President, Corporate Development and Legal Affairs at mmeyer@xdx.com

PRESENTING COMPANIES
Thursday August 25th at 2:10 p.m.

AURA Biosciences, Inc.
U.S.A

Aura Biosciences is applying nanotechnology to the fight against cancer. It has developed the proprietary NanoSmart™ technology platform to enable earlier detection of, and precise treatment of, cancers and distant metastasis. Nanosmart is based on NanoSphere Particles (NSPs) that have a selective tropism for epithelial-derived tumor cells. Aura's unique approach first encapsulates FDA-approved fluorophores into NSPs, a nano-particle that is optimally sized to efficiently move into the diseased tissue, penetrate tumor cells and release the fluorescent cargo in the cytoplasm to enable the real time visualization of tumors and metastasis. In a second step, the same nanoparticle can be used to deliver a chemotherapeutic drug directly to the tumor increasing its efficacy, greatly reducing the overall toxicity and ultimately impacting survival rates. Aura Biosciences is privately held and based in Cambridge, Massachusetts. The company was recognized by the World Economic Forum as a Technology Pioneer; and its Founder and CEO Elisabet de los Pinos was selected by TIME Magazine as one of ten entrepreneurs "that will change your life."

For furhter infotmation visit www.aurabiosciences.com
or contant Elisabet de los Pinos, CEO at epinos@aurabiosciences.com

Kancera AB
SWEDEN

Kancera AB is a biotechnology company, with roots in Pharmacia and the Karolinska Institute, which focuses on the development and sale of drug candidates that have the potential to cure or to stop the progression of cancer. Kancera is currently running two projects, one to develop a treatment for leukemia and one project targeting solid tumor's ability to generate energy in order to survive. At Kancera, we also develop cancer models and stem cell-based techniques that make it possible to study the effect of drug candidates on human tumors, long before start of clinical trials. Our strengths include an experienced Board of Directors, management and organization, two drug candidates with great potential under development, a union of industrial and clinical expertise and access to an internationally validated product development capacity which makes the risky pharmaceutical development more precise. Kancera's operations, including 20 drug discovery and development professionals, are as of September 1st run at the Karolinska Science Park in Solna, Sweden.

For further information visit www.kancera.com
or contact Thomas Olin, CEO at thomas.olin@kancera.com

PledPharma AB
SWEDEN

PledPharma is a Swedish based specialty pharma company focused on developing improved treatments of life-threatening diseases such as cancer and heart disease. In two ongoing clinical phase II programs the company addresses the ability of PLED-derivatives to: 1) protect patients with colorectal cancer undergoing chemotherapy against dose limiting toxicities, and 2) reduce reperfusion injury in patients with acute myocardial infarction treated with percutaneous coronary intervention. The company's proprietary PLED-derivative technology has previously demonstrated protective effects on oxidative stress in preclinical models and in cancer patients. PledPharma's vision is to be the leading specialty pharma company, which develops medicines that prevent normal cells from oxidative stress damage in connection with treatment of life threatening diseases. The company's business model is to develop pharmaceuticals, in areas of large medical need, based on our proprietary technology. The aim is to take the clinical projects through phase IIb and then out-license projects to partners with resources to take them through regulatory approval and to commercial success. PledPharma (STO: PLED) is listed on First North.

For further information visit www.pledpharma.se
or contact Jacques Näsström, CEO at jacques.nasstrom@pledpharma.se

PRESENTING COMPANIES
Friday August 26th at 10:40 a.m.

IMMUNE Pharmaceuticals, Inc.
ISRAEL / U.S.A

IMMUNE Pharmaceuticals is a Monoclonal Antibody (mAb) Development Stage Company based in Israel and in the US. IMMUNE focuses on Inflammation and Cancer with a portfolio of clinical and pre-clinical projects. Our lead mAb, Bertilimumab, was licensed by IMMUNE for all systemic indications from iCo Therapeutics (TSX:ICO) which retains rights for the ophthalmic indications. Bertilimumab, a first-in-class fully human mAb targeting eotaxin-1, was originally developed by Cambridge Antibody Therapeutics, now part of MedImmune, the Biologics Division of AstraZeneca. Bertilimumab has successfully completed phase I/IIa in allergy and will be initially further developed by IMMUNE for Crohn's Disease and Ulcerative Colitis and then for other relevant indications including Severe Asthma. IMMUNE research laboratories are located in Ness-Ziona, Israel and we have established close collaborations with the Weizmann Institute and the Hebrew University of Jerusalem. Our NanoMAbs technology is an alternative to Antibody Drug Conjugates. NanoMabs allow the delivering of micro-doses of cytotoxics to tumor cells and generates a therapeutic response in non responder Antigen expressing patients.

For further information visit www.immunepharmaceuticals.com
or contact Daniel Teper, CEO at d.teper@immunepharma.com

Recopharma AB
SWEDEN

Recopharma has developed a unique technology that uses mucins - naturally occurring, heavily glycosylated proteins produced by epithelial tissues. The Company is focused on R&D of ophthalmic products. The Company's products will provide a natural alternative to the currently available ocular lubricants and tear substitutes, and will be used as a prophylactic against, and treatment for, viral conjunctivitis. Mucins are carriers of carbohydrate receptors for viruses and bacteria binding to host cells during infection. In the eye, mucins form an integral part of the eye's defense against infections, providing a physical barrier to infection as well as molecular decoys for microbes. They can therefore be used as a topical treatment for viral conjunctivitis, for which no curative treatment is currently available. The global market for dry eye products is estimated at c. $1.7 billion (2009) and for ophthalmic anti-infectives to treat conjunctivitis at c. $1.1 billion. Recopharma's technology has many other potential future applications including as vaccine adjuvant. Recopharma's 300 m^2 research facilities are located in the Novum Research Park south of Stockholm close to the southern campus of the Karolinska Institute/Karolinska University Hospital.

For further information visit www.recopharma.com
or contact Jan Holgersson, CSO at jan.holgersson@clinchem.gu.se

TopoTarget AS
DENMARK

Topotarget (NASDAQ OMX: TOPO.CO) is an international biotech company headquartered in Denmark, dedicated to improve cancer therapies. Currently Topotarget has 46 employees and a market cap of EUR 32m. In collaboration with Spectrum Pharmaceuticals Inc. (our US partner for Belinostat) Topotarget currently focuses on the development in clinical studies of its lead drug candidate, belinostat, which has demonstrated an anti-neoplastic effect in both hematological malignancies and solid tumors. Belinostat can be used in combination with full doses of other chemotherapeutic agents, and is currently in a pivotal trial within PTCL (peripheral T-cell lymphoma) and a randomized phase II in cancer of other unknown primary site (CUP). Topotarget's cancer drug target is HDAC. In solid tumors Belinostat is used in the combination with carboplatin and paclitaxel (BelCaP). Based on pre-clinical and clinical results we assess this combination to be the backbone regiment for belinostat use in solid tumors. In addition to PTCL and CUP our lead compound are assessed in multiple clinical trials as a potential treatment for ovarian cancer, small cell lung cancer, thymoma, liver, soft tissue sarcoma, lymphoma, AML, and Myelodysplastic Syndrome (MDS), either alone or in combination with other anti-cancer therapies. Finally Topotarget are generating revenue from Totect® developed from Topotarget's drug discovery technology. Totect® is marketed by the company's own sales specialists in the US.

For further information visit www.topotarget.com
or contact Francois Martelet, CEO at francois.martelet@topotarget.com

RISING STARS
Thursday August 25th at 6:00 p.m.

AddBIO AB
SWEDEN

AddBIO is developing Zolidd, a unique biomaterial product that improves the fixation of orthopedic implants and screws through strengthening of the bone surrounding them. Implant loosening causes patient suffering and is a resource demanding problem, leading to high costs for patient care and re-operations. Compromised bone quality is a significant part of the problem, and improving the strength of the bone surrounding the implant therefore lowers the risk for loosening and other complications. Zolidd is based on research performed by orthopedic surgeon Professor Aspenberg (Sweden). The bone strengthening effect is achieved by binding a bisphosphonate drug onto the implant. Bisphosphonates are already approved drugs that have long been given systemically to osteoporotic patients to improve bone quality. Zolidd now enables these drugs to be released locally, directly from the implant. Zolidd strengthens the surrounding bone without changing the underlying properties of the implant itself. Zolidd is aimed at trauma, spine, and reconstructive orthopedics as well as dental implants. The total orthopedic market is worth approximately 30 billion USD, out of which the estimated addressable market for Zolidd is over 15 billion USD. Efficacy has also been shown in a dental clinical study. Two additional clinical studies are currently on-going, an extended dental study as well as an osteotomy study, results to be expected during the second half of 2011. AddBIO is out to raise 15 MSEK for the finalization of Zolidd development; clinical trials and regulatory approval.

For further information visit www.addbio.se
or contact Trine Vikinge, CEO at trine.vikinge@addbio.se

KalVista Pharmaceuticals, Ltd.
UK

KalVista is a new ophthalmology company with a focus on diabetic macular edema formed in May 2011 following the spin out of discovery assets from Vantia Therapeutics. The Company is developing novel plasma kallikrein inhibitors, which represent a new approach to the treatment of diabetic macular edema, the leading cause of adult blindness in developed countries. KalVista has an advanced pre-clinical product pipeline resulting from over 20 years of leading pharmaceutical discovery in the field of serine protease inhibitors and is targeting both intravitreal injection and oral administration. Plasma kallikrein inhibitors target a distinct molecular pathway central to the pathogenesis of diabetic macular edema, and as such have the potential to offer those patients an effective new treatment option.

For further information visit www.kalvista.com
or contact Andy Crockett, CEO at info@kalvista.com

NoseLabs AB
SWEDEN

NoseLabs has developed an electronic nose that detects ovarian cancer with a sensitivity of 93% and specificity of 91% (tested on about 400 biopsies) - a result that can save lives. The cancer detection potential is however not limited to ovarian cancer; NoseLabs' research also covers alternative types of cancer such as colon and prostate cancer. The electronic nose can detect and identify various substances and has a multitude of application areas (of which several tested), e.g. production quality control, food quality, detection of explosive and health diagnostics. NoseLabs' innovative technology and the electronic nose' unique performance have received wide attention in both national and international media, e.g. Dagens Medicin, Future Oncology and Al Jazeera. The team consists of the innovator behind the electronic nose, Professor Emeritus Thomas Lindblad (Royal Institute of Technology in Stockholm, Sweden) and entrepreneurs, with experience from management consultancies, law firms, running start-ups and raising capital (previously brought in +20 million SEK in fund-raisings).

For further information visit www.noselabs,com
or contact Andreas Törnblad, Co-Founder at andreas@tornblad.se

PCAsso Diagnostics, Inc.
U.S.A.

PCAsso Diagnostics is a start-up diagnostics company developing PolyChromatic Angiography (PCA), the next generation of angiography. The company holds an exclusive worldwide license to develop and market PCA from Columbia University. PCA is a novel imaging technology that utilizes dyes of different colors that provides quantitative analysis of vascular leakage in the retina. The granular information provided by PCA will help ophthalmologists grade disease severity more accurately and tailor treatment accordingly to prevent both under-treatment and over-treatment of retinal vascular diseases. PCA will be used in retinal diseases that have a component of blood retinal barrier dysfunction. The main targeted groups are diabetic retinopathy and age related macular degeneration. It is expected that >100 million patients may benefit from PCA worldwide and approximately 10 million patients in the US.

For further information visit www.pcasso.org
or contact Samir Tari, CEO at samir.tari@pcasso.org

Pink Army Cooperative
U.S.A.

Pink Army is a new approach to developing breast cancer treatments. It is a community-driven, member owned Cooperative operating by open source principles. Using synthetic biology and virotherapy to bring individualized treatments tailored to each patient's DNA and cancer, faster and cheaper than ever before.

For further information visit www.pinkarmy.org
or contact Andrew Hessel, Founder at ahessel@gmail.com

Xbrane AB
SWEDEN

Xbrane Bioscience develops novel technologies for protein production and vaccine development. The company is a spin-off from the world-leading Center for Biomembrane Research (CBR) at Stockholm University, Sweden. Xbrane develops a versatile platform enabling design of efficient, multivalent vaccines that are compatible with nasal administration. In collaboration with academic and industrial partners the company develops vaccine candidates against life-treating diseases. Xbrane Bioscience also develops products for efficient and cost-effective production of proteins and protein based products. Xbrane Bioscience offers a unique proprietary product portfolio and world-leading expertise within bacterial based protein expression.

For further information visit www.xbrane.com
or contact Maria Alriksson, CEO at maria@xbrane.com